Interferon-γ and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: A shift in the Th1-Th2 paradigm

American Journal of Transplantation

Volumn 8, Issue 3, 2008, Pages 547-556

  Famulski, K S ^a   Sis, B ^a   Billesberger, L ^a   Halloran, P F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cell surface molecules; Inflammation; Knockout mice; Macrophages; Transplantation

Indexed keywords

ACTIVIN; ARGINASE 1; GAMMA INTERFERON; GRANZYME; INHIBIN A; INHIBIN B; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 RECEPTOR; MACROPHAGE ELASTASE; MACROPHAGE MANNOSE RECEPTOR 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HOST CELL; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MACROPHAGE ACTIVATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; WILD TYPE;

ACTIVINS; ANIMALS; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON TYPE II; KIDNEY TRANSPLANTATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED STRAINS; NECROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; TH1 CELLS; TH2 CELLS; TISSUE DONORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 39649097138     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02118.x     Document Type: Article

References (51)

1. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002 22 : 317 349.
2. Fairchild RL. The Yin and Yang of IFN-gamma in allograft rejection. Am J Transplant 2003 3 : 913 914.
3. Halloran PF, Afrouzian M, Ramassar V et al. Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. Am J Pathol 2001 158 : 215 226.
4. Mele TS, Kneteman NM, Zhu LF et al. IFN-gamma is an absolute requirement for spontaneous acceptance of liver allografts. Am J Transplant 2003 3 : 942 951.
5. Sis B, Famulski KS, Allanach K, Zhu L-F, Halloran PF. IFN-gamma prevents early perforin-granzyme-mediated destruction of kidney allografts by inducing donor class I products in the kidney. Am J Transplant 2007 7 : 2301 2310.
6. Afrouzian M, Ramassar V, Urmson J, Zhu LF, Halloran PF. Transcription factor IRF-1 in kidney transplants mediates resistance to graft necrosis during rejection. J Am Soc Nephrol 2002 13 : 1199 1209.
7. Sullivan BA, Reed-Loisel LM, Kersh GJ, Jensen PE. Homeostatic proliferation of a Qa-1b-restricted T cell: A distinction between the ligands required for positive selection and for proliferation in lymphopenic hosts. J Immunol 2004 173 : 6065 6071.
8. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 3 : 23 35.
9. Famulski KS, Einecke G, Reeve J et al. Changes in the transcriptome in allograft rejection: IFN-gamma induced transcripts in mouse kidney allografts. Am J Transplant 2006 6 : 1342 1354.
10. Famulski KS, Broderick G, Hay K et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007 7 : 2483 2495.
11. Einecke G, Melk A, Ramassar V et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005 5 : 1827 1836.
12. Mitchell RN, Cotran RS. Cell injury, adaptation, and death. In : Kumar V, Cotran RS, Robbins SL (eds Robbins Basic Pathology. Philadelphia, PA : W.B. Saunders 2003 : 3 31.
13. Kahnert A, Seiler P, Stein M et al. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol 2006 36 : 631 647.
14. Willment JA, Lin HH, Reid DM et al. Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 2003 171 : 4569 4573.
15. Cormier SA, Yuan SB, Dimina D, Lee NA, Lee JJ. Th2 mediated pulmonary inflammation induces the differential expression of a unique eosinophil-associated ribonuclease gene. J Allergy Clin Immunol 2002 109 : S166 S167.
16. Raes G, Brys L, Dahal BK et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 2005 77 : 321 327.
17. Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol 2002 3 : 7.
18. Melzer P, Savchenko V, McKanna JA. Microglia, astrocytes, and macrophages react differentially to central and peripheral lesions in the developing and mature rat whisker-to-barrel pathway: A study using immunohistochemistry for lipocortin1, phosphotyrosine, S100 beta, and mannose receptors. Exp Neurol 2001 168 : 63 77.
19. King NE, Zimmermann N, Pope SM et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 2004 31 : 257 265.
20. Taylor PR, Reid DM, Heinsbroek SE, Brown GD, Gordon S, Wong SY. Dectin-2 is predominantly myeloid restricted and exhibits unique activation-dependent expression on maturing inflammatory monocytes elicited in vivo. Eur J Immunol 2005 35 : 2163 2174.
21. Torocsik D, Bardos H, Nagy L, Adany R. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell Mol Life Sci 2005 62 : 2132 2139.
22. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005 175 : 342 349.
23. Ogawa K, Funaba M, Chen Y, Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 2006 177 : 6787 6794.
24. Hardy CL, O'Connor AE, Yao J et al. Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma. Clin Exp Allergy 2006 36 : 941 950.
25. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: From endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med 2002 227 : 724 752.
26. Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004 114 : 300 308.
27. Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: Lessons drawn from helminth infection and allergy. J Immunol 2006 177 : 1393 1399.
28. Anthony RM, Urban JF Jr., Alem F et al. Memory Th2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat Med 2006 12 : 955 960.
29. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 2004 4 : 583 594.
30. Brys L, Beschin A, Raes G et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005 174 : 6095 6104.
31. Agarwal A, Nick HS. Renal response to tissue injury: Lessons from heme oxygenase-1 gene ablation and expression. J Am Soc Nephrol 2000 11 : 965 973.
32. Abraham NG. Therapeutic applications of human heme oxygenase gene transfer and gene therapy. Curr Pharm Des 2003 9 : 2513 2524.
33. Soares MP, Lin Y, Anrather J et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998 4 : 1073 1077.
34. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002 39 : 531 536.
35. Yamanaka H, Obata K, Fukuoka T et al. Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury. Neuroscience 2005 132 : 183 191.
36. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J 2005 272 : 4858 4867.
37. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) 2005 10 (Suppl) : S11 S13.
38. Richardson J, Viswanathan K, Lucas A. Serpins, the vasculature, and viral therapeutics. Front Biosci 2006 11 : 1042 1056.
39. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005 3 : 1879 1883.
40. Florio P, Gazzolo D, Luisi S, Petraglia F. Activin A in brain injury. Adv Clin Chem 2007 43 : 117 130.
41. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: A sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006 290 : F517 F529.
42. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006 36 (Suppl 3 78 88.
43. Colmenero P, Zhang AL, Qian T et al. Qa-1b-dependent modulation of dendritic cell and NK cell cross-talk in vivo. J Immunol 2007 179 : 4608 4615.
44. Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nature Immunology 2002 3 : 189 195.
45. Ota T, Takeda K, Akiba H et al. IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 2005 106 : 184 192.
46. Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med 1999 190 : 1801 1812.
47. Shiroishi M, Kuroki K, Rasubala L et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A 2006 103 : 16412 16417.
48. Rodriguez NE, Chang HK, Wilson ME. Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect Immun 2004 72 : 2111 2122.
49. Wang H, DeVries ME, Deng S et al. The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection. Nat Med 2000 6 : 549 555.
50. Tanaka K, Yamagami S, Streilein JW. Evidence that T-helper type 2 cell-derived cytokines and eosinophils contribute to acute rejection of orthotopic corneal xenografts in mice. Transplant 2005 79 : 1317 1323.
51. Holan V, Pindjakova J, Krulova M, Neuwirth A, Fric J, Zajicova A. Production of nitric oxide during graft rejection is regulated by the Th1/Th2 balance, the arginase activity, and L-arginine metabolism. Transplant 2006 81 : 1708 1715.